Overview: Bridging the gap in Prescision Oncology
Modern breast cancer management often relies on advanced molecular assays to determine the necessity of chemotherapy. While these tests provide critical insights, they are associated with high financial costs,often exceeding $4,000 USD per patient and can result in diagnostic wait times of nearly a month.
Our research introduces a sophisticated clinical screening framework designed to triage patients effectively. By utilizing data already available during routine pathology, we can identify which patients will benefit most from advanced molecular testing and which can safely proceed with a treatment plan based on immediate clinical findings
Key Information
Our team has validated a high-precision screening tool that integrates standard tumor characteristics to estimate a patient’s molecular risk profile.This approach allows for:
- Rapid Risk Assessment: By analyzing tumor size, grade, and biomarker status through a refined analytical model, we provide results far faster than traditional molecular assays.
- Resource Optimization: Our findings indicate that a significant portion of patients (up to 69%) can be accurately categorized without the need for expensive additional testing.
- Clinical Accuracy: In our extensive validation studies, the screening tool demonstrated 100% agreement with definitive high- and low-risk categories, ensuring no compromise in patient safety.
This study represents a landmark effort in validating these protocols within diverse clinical populations, including the first comprehensive assessment in a Canadian cohort.
Key Benefits of the Framework:
- Economic Sustainability: Implementing this triage method could potentially save the healthcare system over $40 million annually by reducing unnecessary testing.
- Patient Well-being: By providing immediate results, we help two-thirds of patients avoid the prolonged anxiety typically associated with waiting weeks for molecular test results.
- Standardized Integration: Our methods are designed to be easily incorporated into existing pathology reporting software, requiring no additional manual labor from clinical staff.
We are committed to the ongoing refinement of our predictive algorithms. Current efforts include expanding our research to larger international cohorts and exploring how these clinical screening tools can better predict long-term patient outcomes and survival.